TriSalus Life Sciences (NASDAQ:TLSI) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of TriSalus Life Sciences (NASDAQ:TLSI) from a hold rating to a sell rating in a report released on Sunday.

Other research analysts also recently issued reports about the company. Zacks Research upgraded TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 29th. Finally, Canaccord Genuity Group lifted their price target on TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $11.00.

TriSalus Life Sciences Trading Up 0.7%

TLSI stock opened at $4.55 on Friday. The stock has a 50-day moving average price of $6.14 and a two-hundred day moving average price of $5.27. TriSalus Life Sciences has a 1 year low of $3.42 and a 1 year high of $7.95. The stock has a market cap of $227.32 million, a PE ratio of -2.25 and a beta of 0.42.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.79). The firm had revenue of $11.57 million during the quarter, compared to the consensus estimate of $11.76 million. On average, analysts forecast that TriSalus Life Sciences will post -1.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TriSalus Life Sciences

Institutional investors have recently modified their holdings of the business. Bank of America Corp DE lifted its stake in shares of TriSalus Life Sciences by 1.8% in the 2nd quarter. Bank of America Corp DE now owns 188,906 shares of the company’s stock valued at $1,030,000 after acquiring an additional 3,374 shares during the last quarter. Connective Capital Management LLC boosted its stake in shares of TriSalus Life Sciences by 12.8% during the second quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock valued at $179,000 after purchasing an additional 3,717 shares in the last quarter. Millennium Management LLC grew its holdings in shares of TriSalus Life Sciences by 17.7% during the third quarter. Millennium Management LLC now owns 35,612 shares of the company’s stock worth $166,000 after purchasing an additional 5,359 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of TriSalus Life Sciences in the second quarter valued at approximately $29,000. Finally, JPMorgan Chase & Co. raised its holdings in TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after buying an additional 7,519 shares during the last quarter. Institutional investors and hedge funds own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.